Low-Dose Testosterone: What the Evidence and Labels Say

Key points

• Testosterone is a US prescription drug, Schedule III, approved for men whose bodies make too little of it because of a medical condition. The label says age-related decline alone is not an indication [1][2].
• The largest trial, TRAVERSE (5,246 men with low testosterone, symptoms and cardiovascular risk, about 33 months of follow-up), found no excess of heart attack, stroke or cardiovascular death. It did find more atrial fibrillation, acute kidney injury and pulmonary embolism, and more fractures [3][5].
• Testosterone suppresses sperm production. Guidelines advise against it in men who want children [1][7][8].
• We found no trial that tests testosterone in men whose levels are normal, so the benefit-risk balance there is unknown.
• A viral looksmaxxing list rates “low dose test” A tier. The trial evidence does not support that placement.

What it is and who it is approved for

Testosterone is the main male sex hormone. As a drug it is prescribed to replace it when the body does not make enough. The injectable label we opened (testosterone enanthate, DailyMed, version dated 18 June 2026) lists replacement therapy “in conditions associated with a deficiency or absence of endogenous testosterone”, with primary hypogonadism (a testicular cause) and hypogonadotropic hypogonadism (a pituitary or hypothalamic cause) named. It also lists delayed puberty in males [1].

The same label states that safety and efficacy in men with age-related hypogonadism have not been established, and that replacement “is not indicated” in older patients with age-related hypogonadism only [1].

Regulatory status

Item	Status	Source
US approval (FDA)	Prescription drug for male hypogonadism with a deficiency or absence of testosterone	[1]
US scheduling	Schedule III controlled substance under the Controlled Substances Act	[1]
Age-related decline	“Limitation of Use” kept by the FDA after TRAVERSE (28 Feb 2025)	[2]
Blood pressure	FDA: ABPM studies “confirmed an increase in blood pressure with use of all testosterone products, class-wide”; warnings added	[2]
Cardiovascular boxed-warning language	FDA is removing the language about increased cardiovascular risk; TRAVERSE results go on all labels	[2]

We checked the US label and the FDA statement only. UK, German and EMA status were not checked.

The abuse and dependence section of the label says serious adverse reactions “have been reported in individuals who abuse anabolic androgenic steroids”. Non-medical use of testosterone exists and has documented harms; this article does not cover it further [1].

Other label warnings we read: it can raise blood pressure and is “not recommended” in uncontrolled hypertension; hemoglobin and hematocrit should be checked periodically for polycythemia; postmarketing reports include deep vein thrombosis and pulmonary embolism; elderly patients on androgens “may be at an increased risk” of prostatic hypertrophy and prostate cancer, and androgens are contraindicated in known or suspected prostate cancer [1].

What the T Trials found

The Testosterone Trials (Snyder et al., New England Journal of Medicine, 2016) enrolled 790 men aged 65 or older with testosterone below 275 ng/dL and symptoms suggesting low androgen levels. They received testosterone gel or placebo gel for one year in up to three linked trials [4].

• Testosterone rose to the mid-normal range for young men.
• Sexual activity, desire and erectile function improved significantly.
• Across the three trials, 20.5% of treated men and 12.6% on placebo gained at least 50 metres in a six-minute walk (P=0.003). The Physical Function Trial alone showed no significant difference.
• Vitality (fatigue scale) did not improve significantly. Mood and depressive symptoms were slightly better.
• Adverse events were similar, but the authors said the sample was too small to judge risk [4].

Funding: the National Institutes of Health and others. The abstract record we opened did not state whether a manufacturer took part [4].

What TRAVERSE found

TRAVERSE (Lincoff et al., NEJM, 2023) was a randomized, double-blind, placebo-controlled non-inferiority trial. It enrolled 5,246 men aged 45 to 80 with symptoms of hypogonadism, two fasting testosterone readings below 300 ng/dL, and either existing cardiovascular disease or high risk. Men received a 1.62% testosterone gel, adjusted to keep levels in a 350 to 750 ng/dL range, or placebo gel. It was funded by AbbVie and others [3].

Mean treatment lasted 21.7 months and mean follow-up 33.0 months [3].

Outcome	Result	Source
Cardiovascular death, non-fatal heart attack or stroke	182 (7.0%) testosterone vs 190 (7.3%) placebo; HR 0.96 (95% CI 0.78-1.17); non-inferiority met	[3]
Atrial fibrillation, acute kidney injury, pulmonary embolism	Higher with testosterone	[3]
Clinical fractures (sub-trial, 5,204 men, median follow-up 3.19 years)	91 (3.50%) vs 64 (2.46%); HR 1.43 (95% CI 1.04-1.97). Authors: testosterone did not lower fractures. Funded by AbbVie and others	[5]
Anaemia, men with anaemia at start (815 men)	Remission at 12 months 45.0% vs 33.9%; overall P=.002. Men without anaemia developed it less often	[6]
High-grade prostate cancer (5,204 men, 14,304 person-years)	5 of 2,596 (0.19%) vs 3 of 2,602 (0.12%); HR 1.62 (95% CI 0.39-6.77); not significant	[7]

Limits of the prostate result: men with PSA above 3.0 ng/mL or severe urinary symptoms were excluded, and PSA rose more on testosterone than on placebo [7]. Treatment averaged under two years, so longer-term safety is not answered. The funding statements of the anaemia and prostate papers were not in the records we opened; some authors list AbbVie affiliations [6][7].

Two points on reading these results. TRAVERSE tested men with documented low levels, not healthy men. And “no excess of major cardiac events” is not “no harm”: the pulmonary embolism, atrial fibrillation and fracture signals came from the same trial.

What the guidelines say

• Endocrine Society (2018): diagnose hypogonadism only in men with symptoms and signs plus “unequivocally and consistently low” testosterone on repeated fasting morning tests; investigate the cause; recommend against starting in men planning fertility in the near term, with PSA above 4 ng/mL, or with a heart attack or stroke in the previous six months. This predates TRAVERSE. We read the abstract only [8].
• American Urological Association: the guideline was published in 2018 and its validity confirmed in 2024. The public page says deficiency requires both low levels and symptoms or signs. The statements themselves are behind a member login, so we could not check them [9].
• European Association of Urology (2026 limited update): strong recommendation: “Do not use testosterone therapy for the treatment of male infertility and in men wishing to be fathers”; measure total testosterone in the morning, fasting. We read excerpts of the web guideline [10].

Fertility

Testosterone from outside the body signals the pituitary to reduce the hormones that drive sperm production. The label says that at large doses spermatogenesis “may also be suppressed”, and that men abusing androgens may experience subfertility and infertility [1]. The EAU and the Endocrine Society both advise against use in men who want children [8][10]. We did not verify how fast or how often sperm counts recover after stopping, so we make no claim on it.

Risks and unknowns

• Documented: raised blood pressure; atrial fibrillation, acute kidney injury and pulmonary embolism in TRAVERSE; more fractures; polycythemia; suppressed sperm production; possible prostate effects, with limited follow-up [1][2][3][5][7].
• Populations at risk: men with uncontrolled hypertension, prostate cancer, clotting history, or an interest in fatherhood [1][8][10].
• Not studied: we found no randomized trial of testosterone in men with normal levels to improve appearance, and the trials above enrolled men with documented deficiency. We could not run further searches after a search limit, so this is “not found”, not “does not exist”. Outcomes beyond about three years are also unknown.
• Not verified: a June 2026 press report of a proposed change to the US age limitation; the AUA statements; UK, German and EMA status.

What the tier list claims, and a verdict

On 22 October 2026 @Hoostethics posted a “ranking looksmaxxing techniques” tier list that places “low dose test (testosterone enanthate)” in A tier [11]. The post gives no criteria and no definition of “low dose”. Our fuller review of that list is in the looksmaxxing tier-list evidence check.

Verdict: not supported. The approved use is treating a diagnosed deficiency. In that population, TRAVERSE showed no excess of major cardiac events but did show more atrial fibrillation, kidney injury, pulmonary embolism and fractures, plus a class-wide blood pressure increase and effects on fertility [2][3][5]. For men with normal testosterone, we found no trial at all. A top-tier rating implies strong benefit and acceptable harm; neither is shown.

Frequently asked questions

Is testosterone therapy approved for men with normal testosterone? No. The US label covers men with a deficiency or absence of testosterone and says age-related decline alone is not an indication [1].

Did TRAVERSE show testosterone is safe for the heart? It showed no excess of major cardiac events over about 33 months in men with low testosterone and cardiovascular risk. It also found more atrial fibrillation, acute kidney injury and pulmonary embolism [3].

Does testosterone affect fertility? Yes. Outside testosterone can suppress sperm production, and the EAU and Endocrine Society advise against it in men who want children [1][8][10].

Why is testosterone a controlled substance? The US label lists it as Schedule III and carries an abuse and dependence section [1].

Sources

1. Eugia, “Testosterone enanthate injection” label, DailyMed (version dated 18 Jun 2026). https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=82a98132-9d5f-40a5-8c4f-f52f2a5de60e
2. FDA, “FDA issues class-wide labeling changes for testosterone products” (28 Feb 2025). http://www.fda.gov/drugs/drug-alerts-and-statements/fda-issues-class-wide-labeling-changes-testosterone-products
3. Lincoff AM et al., “Cardiovascular Safety of Testosterone-Replacement Therapy”, N Engl J Med 389:107-117 (2023). https://pubmed.ncbi.nlm.nih.gov/37326322/ (abstract read via Europe PMC)
4. Snyder PJ et al., “Effects of Testosterone Treatment in Older Men”, N Engl J Med 374:611-624 (2016). https://pubmed.ncbi.nlm.nih.gov/26886521/ (via Europe PMC)
5. Snyder PJ et al., TRAVERSE fracture sub-trial, N Engl J Med 390:203-211 (2024). https://pubmed.ncbi.nlm.nih.gov/38231621/ (via Europe PMC)
6. “Efficacy of Testosterone Replacement Therapy in Correcting Anemia in Men With Hypogonadism: A Randomized Clinical Trial”, JAMA Netw Open (2023). https://pubmed.ncbi.nlm.nih.gov/37889486/ (via Europe PMC)
7. Bhasin S et al., “Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism”, JAMA Netw Open (2023). https://pubmed.ncbi.nlm.nih.gov/38150256/ (via Europe PMC)
8. Bhasin S et al., “Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline”, J Clin Endocrinol Metab 103:1715-1744 (2018). https://pubmed.ncbi.nlm.nih.gov/29562364/ (abstract only)
9. American Urological Association, “Evaluation and Management of Testosterone Deficiency (2024)”. https://www.auanet.org/guidelines-and-quality/guidelines/testosterone-deficiency-guideline (public summary only)
10. European Association of Urology, “Sexual and Reproductive Health” guidelines, 2026 limited update. https://uroweb.org/guidelines/sexual-and-reproductive-health (excerpts only)
11. @Hoostethics, “ranking looksmaxxing techniques” (X post, 22 Oct 2026). https://x.com/Hoostethics/status/2113302148750758106 (list transcribed in the project’s source file)

This article is information, not medical advice.